Anti-Angiogenic Activity of Rotenoids from the Stems of Derris trifoliata

Abstract

The plants in the genus Derris have proven to be a rich source of rotenoids, of which cytotoxic effect against cancer cells seem to be pronounced. However, their effect on angiogenesis playing a crucial role in both cancer growth and metastasis has been seldom investigated. This study aimed at investigating the effect of the eight rotenoids (1–8) isolated from Derris trifoliata stems on three cancer cells and angiogenesis. Among them, 12a-hydroxyrotenone (2) exhibited potent inhibition on both cell growth and migration of HCT116 colon cancer cells. Further, anti-angiogenic assay in an ex vivo model was carried out to determine the effect of the isolated rotenoids on angiogenesis. Results revealed that 12a-hydroxyrotenone (2) displayed the most potent suppression of microvessel sprouting. The in vitro assay on human umbilical vein endothelial cells was performed to determine whether compound 2 elicits anti-angiogenic effect and its effect was found to occur via suppression of endothelial cells proliferation and tube formation, but not endothelial cells migration. This study provides the first evidence that compound 2 could potently inhibit HCT116 cancer migration and anti-angiogenic activity, demonstrating that 2 might be a potential agent or a lead compound for cancer therapy.

Key words

rotenoid - Derris trifoliata - Leguminosae - cytotoxicity - anti-angiogenesis - cancer - cell migration

• References

• 1 Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 Cancer Groups, 1990 to 2015. A systematic analysis for the global burden of disease study. JAMA Oncol 2017; 3: 524-548
• 2 GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1659-1724
• 3 Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257
• 4 Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307
• 5 Deyou T, Gumula I, Pang F, Gruhonjic A, Mumo M, Holleran J, Duffy S, Fitzpatrick PA, Heydenreich M, Landberg G, Derese S, Avery V, Rissanen K, Erdelyi M, Yenesew A. Rotenoids, flavonoids, and chalcones from the root bark of Millettia usaramensis . J Nat Prod 2015; 78: 2932-2939
• 6 Lu HY, Liang JY, Yu P, Chen XY. Rotenoids from the root of Derris elliptica (Roxb.) Benth. II. Chin J Nat Med 2009; 7: 24-27
• 7 Deng YT, Huang HC, Lin JK. Rotenone induces apoptosis in MCF-7 human breast cancer cell-mediated ROS through JNK and p38 signaling. Mol Carcinog 2010; 49: 141-151
• 8 Ito C, Itoigawa M, Kojima N, Tan HTW, Takayasu J, Tokuda H, Nishio H, Furukawa H. Cancer chemopreventive activity of rotenoids from Derris trifoliata . Planta Med 2004; 70: 585-588
• 9 Kim JH, Kim JH, Yu YS, Park KH, Kang HJ, Lee GY, Kim KW. Antiangiogenic effect of deguelin on choroidal neovascularization. J Pharmcol Exp Ther 2008; 324: 643-647
• 10 Tewtrakul S, Cheenpracha S, Karalia C. Nitric oxide inhibitory principles from Derris trifoliata stems. Phytomedicine 2009; 16: 568-572
• 11 Yenesew A, Mushibe EK, Induli M, Derese S, Midiwo JO, Kabaru JM, Heydenreich M, Koch A, Peter MG. 7a-O-methyldeguelol, a modified rotenoid with an open ring-C, from the roots of Derris trifoliata . Phytochemistry 2005; 66: 653-657
• 12 Yenesew A, Kiplagat JT, Derese S, Midiwo JO, Kabaru JM, Heydenreich M, Peter MG. Two unusual rotenoid derivatives, 7a-O-methyl-12a-hydroxydeguelol and spiro-13-homo-13-oxaelliptone, from the seeds of Derris trifoliata . Phytochemistry 2006; 67: 988-991
• 13 Pangkam N, Chimsook T. The structure activity relationship and cytotoxicity between stemonal and 6-deoxyclitoriacetal. Adv Mat Res 2013; 699: 698-702
• 14 Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B 2015; 5: 402-418
• 15 Fang Y, Chen Y, Yu L, Zheng C, Qi Y, Li Z, Yang Z, Zhang Y, Luo J, Liu M. Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1. J Natl Cancer Inst 2013; 105: 47-58
• 16 Pienta KJ, Naik H, Akhtar A, Yamazaki K, Reploqle TS, Lehr J, Donat TL, Tait L, Hogan V, Raz A. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 1995; 87: 348-353
• 17 Shinkaruk S, Bayle M, Laїn G, Déléris G. Vascular endothelial cell growth factor (VEGF), and emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents 2003; 3: 95-117
• 18 Feng J, Zhang XJ, Xing D. Low-power laser irradiation (LPLI) promotes VEGF expression and vascular endothelial cell proliferation through the activation of ERK/Sp1 pathway. Cell Signal 2012; 14: 1116-1125
• 19 Kayashima T, Mori M, Yoshida H, Mizushina Y, Matsubara K. 1, 4-Naphthoquinone is a potent inhibitor of human cancer cell growth and angiogenesis. Cancer Lett 2009; 278: 34-40
• 20 Ferrrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999; 237: 1-30